Verwey, Charl
Madhi, Shabir A.
Funding for this research was provided by:
University of the Witwatersrand
Article History
Accepted: 16 March 2023
First Online: 25 April 2023
Declarations
:
: Open access funding provided by University of the Witwatersrand.
: Charl Verwey has previously received personal funding from AstraZeneca, Merck, and GSK. Shabir A. Madhi has received grant support to the institution from the Bill & Melinda Gates Foundation (BMGF) and has been involved in clinical trials with Pfizer, GSK, Merck, and AstraZeneca, with funding to the institution. Charl Verwey and Shabir A. Madhi declare no conflicts of interest in relation to this manuscript.
: No ethics approval was required.
: Not applicable.
: All data represented are available in the public domain.
: Not applicable.
: This manuscript is the sole work of the authors. CV and SAM contributed equally to the planning, development, writing, and final approval of the manuscript.